Shanghai Henlius Biotech: The Cash-Flow Story Behind the '64% Below Fair Value' Headline

The headline that Shanghai Henlius Biotech is trading "64% below fair value" is catchy. It is also almost certainly wrong — or at the very least, so dependent on assumptions that no serious investor should take it at face value. The fair-value models producing deep-discount figures assume Henlius' free cash flow will grow from roughly RMB 82 million today to RMB 2.1 billion by 2029. That is a 25-fold increase in less than four years. If that happens, the stock is dirt cheap. If it doesn't, the current price may be more than generous.

The real story is what the cash flows actually say about this business right now.

Let me start with the operations. Henlius reported full-year 2025 results on March 20, 2026, and the top line is genuinely strong. Revenue reached RMB 6.67 billion, up 16.5% year-over-year. Pre-R&D profit — operating earnings before the company's massive research spend — came in at RMB 2.34 billion, up 26.2%. That kind of margin leverage tells you the commercial engine is working. The trastuzumab franchise, Henlius' cash cow, generated RMB 3.27 billion in global breast-cancer-related sales. Serplulimab, their innovative anti-PD-1 antibody approved in over 40 countries, hit RMB 1.49 billion, up 13.7%. Neratinib surged 564% to RMB 301 million. Bevacizumab jumped 81% to RMB 356 million.

The pipeline milestones are equally real. Pertuzumab (HLX11) became the first and only pertuzumab biosimilar approved in the United States in the second half of 2025. Denosumab (HLX14) received approvals in the US, EU, and UK and generated RMB 9.8 million in its first partial year of sales. Serplulimab is targeting a US Biologics License Application submission in 2026 — a potential inflection point if approved, as it would mark the first China-developed PD-1 inhibitor with US regulatory clearance. Henlius is also advancing HLX43, a PD-L1 antibody-drug conjugate showing early signal in non-small-cell lung cancer and head-and-neck cancer, and targeting more than 20 product approvals globally through 2030.

The commercial and scientific case checks out. Now let's talk about cash flow and what the market is actually paying for it.

Henlius' operating cash flow for fiscal 2025 was RMB 1.31 billion. That sounds healthy. But here is the catch: in the first half of 2025, cash inflows from business development agreements — licensing deals and upfront payments to partners like Sandoz for the ipilimumab biosimilar — exceeded RMB 1 billion, up 280% year-over-year. Those inflows boosted H1 operating cash flow by a reported 207%. Strip out one-time BD proceeds, and the underlying operating cash generation from product sales is materially lower. For a company whose valuation depends on future cash flows, distinguishing between recurring cash generation and front-loaded licensing receipts is not a detail — it is the entire basis of the model.

On the investing side, Henlius spent RMB 1.20 billion on capital expenditures in 2025, largely on the Songjiang manufacturing facility that received EU GMP certification in July 2025 and whose second phase completed in August 2025. The company is investing heavily in production capacity. The result: sustainable free cash flow — the cash left after maintaining and growing the business — sits in a much narrower band than the operating cash flow headline suggests. The DCF models flagging deep undervaluation use a trailing twelve-month free cash flow figure of CN¥82.2 million as their base year. That is the starting point from which they project to CN¥2.1 billion by 2029.

The R&D spend is the other side of the coin. Henlius invested RMB 2.49 billion in research during 2025, up 35.4% from the prior year. Pre-R&D profit was RMB 2.34 billion. After R&D, net profit was RMB 827 million — a net margin of 12.4%. The company is generating real earnings, but the R&D burden is enormous and accelerating faster than revenue. That is normal for a biotech in the innovation-to-commercialization transition, but it means profitability gains from top-line growth are being redirected into the pipeline rather than flowing to shareholders.

From a valuation perspective, the stock trades around HK$67, implying a market capitalization of HK$30.3 billion and an enterprise value of HK$33.6 billion. The price-to-sales ratio is 3.9x. The price-to-earnings ratio runs 41x to 44x depending on whether you use trailing or consensus figures. The balance sheet carries approximately RMB 3.88 billion in total debt against RMB 12.36 billion in total assets. The company is not leveraged to the hilt, but the debt is meaningful relative to the RMB 827 million in annual net profit.

Now here is where the "64% below fair value" claim collapses under scrutiny. The DCF model producing deep-discount figures assumes Henlius will grow from a near-zero free-cash-flow base to RMB 2.1 billion by 2029. For context, the company's entire 2025 revenue was RMB 6.67 billion. The model is assuming free cash flow margins will reach roughly 31% by 2029 — higher than most mature biopharma companies achieve. It also requires R&D spending to plateau or decline even as the company pushes toward 20 global product approvals and a US BLA for serplulimab. That is not impossible. It is an assumption that needs to earn its place in your investment case, not a given.

A different lens is the analyst consensus. Six analysts covering the stock have a 12-month average price target of HK$103, with a high estimate of HK$120. That implies roughly 54% upside from the current HK$67 level. Analyst targets are not infallible, and they often trail reality during rapid growth periods. But a consensus gap of that magnitude — across six independent coverage teams — suggests that even professional forecasters believe the stock is not fully reflecting its near-catalyst exposure: the US serplulimab BLA submission planned for 2026, denosumab scale-up in Western markets, and the continued expansion of the trastuzumab franchise across 50-plus countries.

While it's true that the DCF fair-value exercise is the most dramatic framing you will find, I would argue that the analyst consensus gap is the more credible yardstick. It does not require a 25-fold free cash flow multiplication. It requires serplulimab to gain US market access, the pipeline approvals to materialize on schedule, and R&D intensity to moderate as the product portfolio widens. Those are big asks, but they are the asks already embedded in the RMB 6.67 billion revenue trend.

Even if serplulimab's US filing faces regulatory headwinds — and Chinese-developed first-in-class biologics have a historically mixed track record with the FDA — the trastuzumab franchise alone provides a durable cash floor. At RMB 3.27 billion in global franchise sales and with approvals spanning more than 50 countries, it is a global-scale biosimilar that does not require further clinical validation to grow. Adding neratinib for combination therapy, a newly approved pertuzumab biosimilar in the US, and denosumab across Western markets gives Henlius a broader revenue base than most Chinese biotechs at a comparable stage.

From a balance-sheet perspective, RMB 3.88 billion in debt against RMB 12.36 billion in total assets is manageable. The company generates positive operating cash flow every quarter — even without counting BD proceeds — and the ex-China revenue segment is growing fast, having doubled year-over-year to exceed RMB 200 million with RMB 93.9 million in profit. This is not a company on the verge of a liquidity crisis. It is a company whose valuation depends on execution risk rather than survival risk.

All things considered, the "64% below fair value" headline is a methodological mirage — a DCF model dressed up as a price target, built on growth assumptions that would make most mature pharma companies look like penny stocks. The stock is not fantastically undervalued on a free-cash-flow basis, because the free cash flow base is still thin and the path to RMB 2.1 billion is an assumption, not a pipeline guarantee. But the analyst consensus gap of roughly 54%, the accelerating commercial revenue, and the density of 2026 catalysts suggest the market is not pricing in a base-case outcome for the pipeline.

I would rate Henlius a Buy at current levels, with the caveat that the entry thesis is pipeline optionality, not deep intrinsic value. The risk is not that the company fails — the balance sheet can sustain the R&D burn — but that regulatory timelines slip, R&D intensity stays elevated longer than expected, or the Chinese biotech multiple compression that has plagued the sector resurfaces. If you need a margin of safety built on today's cash flows, this is not the trade. If you are willing to buy the optionality of a US-approved serplulimab and a global biosimilar platform at a price where consensus analysts see HK$103+, the risk-reward still works.